Key inclusion criteria  Treatment with metformin as monotherapy for a period of at least 90 days prior to eligibility assessment. Current member of a health plan which includes pharmacy benefits. HbA1c greater than or equal to 7% within last 90 days prior to the day of screening or to be taken before randomization. Further intensification with an additional glucose-lowering oral agent including oral semaglutide is indicated according to approved prescribing information to achieve glycemic target at the discretion of the treating physician.  Key exclusion criteria:  Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using contraception. Any disorder which in the investigator's or treating physician's opinion might jeopardize patient's safety.